PURPOSE: ABCG2 overexpression has been linked to resistance to topoisomerase inhibitors, leading us to examine the potential interaction between ABCG2 and becatecarin. METHODS: Interaction with ABCG2 was determined by ATPase assay, competition of [(125)I]iodoarylazidoprazosin (IAAP) photolabeling and flow cytometry. Cellular resistance was measured in 4-day cytotoxicity assays. ABCG2 expression was measured by fluorescent-substrate transport assays and immunoblot. RESULTS: Becatecarin competed [(125)I]-IAAP labeling of ABCG2, stimulated ATPase activity and, at concentrations greater than 10 microM, inhibited ABCG2-mediated transport. Becatecarin-selected A549 Bec150 lung carcinoma cells were 3.1-, 15-, 8-, and 6.8-fold resistant to becatecarin, mitoxantrone, SN-38 and topotecan, respectively. A549 Bec150 cells transported the ABCG2 substrates pheophorbide a, mitoxantrone and BODIPY-prazosin and displayed increased staining with the anti-ABCG2 antibody 5D3 compared to parental cells. Increased ABCG2 expression was confirmed by immunoblot. CONCLUSIONS: Our results suggest that becatecarin is transported by ABCG2 and can induce ABCG2 expression in cancer cells.
PURPOSE:ABCG2 overexpression has been linked to resistance to topoisomerase inhibitors, leading us to examine the potential interaction between ABCG2 and becatecarin. METHODS: Interaction with ABCG2 was determined by ATPase assay, competition of [(125)I]iodoarylazidoprazosin (IAAP) photolabeling and flow cytometry. Cellular resistance was measured in 4-day cytotoxicity assays. ABCG2 expression was measured by fluorescent-substrate transport assays and immunoblot. RESULTS:Becatecarin competed [(125)I]-IAAP labeling of ABCG2, stimulated ATPase activity and, at concentrations greater than 10 microM, inhibited ABCG2-mediated transport. Becatecarin-selected A549 Bec150 lung carcinoma cells were 3.1-, 15-, 8-, and 6.8-fold resistant to becatecarin, mitoxantrone, SN-38 and topotecan, respectively. A549 Bec150 cells transported the ABCG2 substrates pheophorbide a, mitoxantrone and BODIPY-prazosin and displayed increased staining with the anti-ABCG2 antibody 5D3 compared to parental cells. Increased ABCG2 expression was confirmed by immunoblot. CONCLUSIONS: Our results suggest that becatecarin is transported by ABCG2 and can induce ABCG2 expression in cancer cells.
Authors: T Yoshinari; M Ohkubo; K Fukasawa; S Egashira; Y Hara; M Matsumoto; K Nakai; H Arakawa; H Morishima; S Nishimura Journal: Cancer Res Date: 1999-09-01 Impact factor: 12.701
Authors: Kuniaki Morisaki; Robert W Robey; Csilla Ozvegy-Laczka; Yasumasa Honjo; Orsolya Polgar; Kenneth Steadman; Balázs Sarkadi; Susan E Bates Journal: Cancer Chemother Pharmacol Date: 2005-04-19 Impact factor: 3.333
Authors: V Koneti Rao; Darawalee Wangsa; Robert W Robey; Lyn Huff; Yasumasa Honjo; Jeffrey Hung; Turid Knutsen; Thomas Ried; Susan E Bates Journal: Cancer Genet Cytogenet Date: 2005-07-15
Authors: Alejandro D Ricart; Lisa A Hammond; John G Kuhn; Chris H Takimoto; Andrew Goetz; Bahram Forouzesh; Leonardo Forero; Jose L Ochoa-Bayona; Kristin Berg; Anthony W Tolcher; Eric K Rowinsky Journal: Clin Cancer Res Date: 2005-12-15 Impact factor: 12.531
Authors: Harold J Burstein; Beth Overmoyer; Rebecca Gelman; Paula Silverman; Jennifer Savoie; Kathryn Clarke; Leda Dumadag; Jerry Younger; Percy Ivy; Eric P Winer Journal: Invest New Drugs Date: 2006-09-13 Impact factor: 3.850
Authors: C Brendel; C Scharenberg; M Dohse; R W Robey; S E Bates; S Shukla; S V Ambudkar; Y Wang; G Wennemuth; A Burchert; U Boudriot; A Neubauer Journal: Leukemia Date: 2007-03-22 Impact factor: 11.528
Authors: Matthew D Hall; Kyle R Brimacombe; Matthew S Varonka; Kristen M Pluchino; Julie K Monda; Jiayang Li; Martin J Walsh; Matthew B Boxer; Timothy H Warren; Henry M Fales; Michael M Gottesman Journal: J Med Chem Date: 2011-08-01 Impact factor: 7.446
Authors: Kenneth K W To; Robert W Robey; Turid Knutsen; Zhirong Zhan; Thomas Ried; Susan E Bates Journal: Mol Cancer Ther Date: 2009-10 Impact factor: 6.261